The cost-effectiveness of intensive therapy for diabetes mellitus

Endocrinology and Metabolism Clinics of North America

Volumn 26, Issue 3, 1997, Pages 679-695

  Herman, W H ^a   Dasbach, E J ^a   Songer, T J ^a   Eastman, R C ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; MEVINOLIN; SIMVASTATIN;

BLINDNESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH PROGRAM; HEALTH PROMOTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LASER COAGULATION; LEG AMPUTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030792841     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70274-7     Document Type: Article

References (37)

1. American Diabetes Association Direct and Indirect Costs of Diabetes in the United States in 1992 1993 ADA Alexandria, VA
2. K.M. Anderson P.M. Odell R.W.F. Wilson Cardiovascular disease risk profiles Am Heart J 121 1990 293 298
3. D.J. Ballard L.L. Humphrey J. Melton III Epidemiology of persistent proteinuria in type II diabetes mellitus Diabetes 37 1988 405 412
4. Y.P. Chiang L.J. Bassi J.C. Javitt Federal budgetary costs of blindness Millbank Q 70 1992 319 340
5. P.J. Dyck K.M. Kratz J.L. Karnes The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester diabetic neuropathy study Neurology 43 1993 817 824
6. P.C. Eastman J.C. Javitt W.H. Herman Model of complications of non–insulin dependent diabetes mellitus. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia Diabetes Care 20 1997 735 744
7. R.C. Eastman J.C. Javitt W.H. Herman Model of complications of non–insulin dependent diabetes mellitus. I. Model construction and assumptions Diabetes Care 20 1997 725 734
8. M.H. Eckman S. Greenfield W.C. Mackey Foot infections in diabetic patients: Decision and cost-effectiveness analyses JAMA 273 1995 712 720
9. J.M. Eisenberg Clinical economics: A guide to the economic analysis of clinical practices JAMA 262 1989 2879 2886
10. S.A. Finkler The distinction between costs and charges Ann Intern Med 96 1982 102 109
11. J.F. Fries C.E. Koop C.E. Beadle the Health Project Consortium Reducing health care costs by reducing the need and demand for medical services N Engl J Med 329 1993 321 325
12. L.S. Geiss W.H. Herman P.J. Smith Mortality in noninsulin-dependent diabetes M.I. Harris C.C. Cowie M.P. Stern Diabetes in America ed 2 1995 US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, National Diabetes Data Group Bethesda, MD
13. M.R. Gold J.E. Siegel L.B. Russell Cost-effectiveness in Health and Medicine 1996 Oxford University Press New York
14. E.I. Hatziandreu J.P. Koplan M.C. Weinstein A cost-effectiveness analysis of exercise as a health promotion activity Am J Public Health 78 1988 1417 1421
15. L.L. Humphrey D.J. Ballard P.P. Frohnert Chronic renal failure in noninsulin-dependent diabetes mellitus Ann Intern Med 111 1989 788 796
16. L.L. Humphrey P.J. Palumbo M.A. Butters The contribution of noninsulin–dependent diabetes to lower-extremity amputation in the community Arch Intern Med 154 1994 885 892
17. J.C. Javitt L.P. Aiello Y. Chiang Preventive eye care in people with diabetes is cost-saving to the federal government: Implications for health-care reform Diabetes Care 17 1994 909 917
18. M. Johannesson B. Jonsson J. Kjekshus for the Scandinavian Simvastatin Survival Study Group Cost-effectiveness of Simvastatin treatment to lower cholesterol levels in patients with coronary heart disease N Engl J Med 336 1997 332 336
19. R.M. Kaplan J.P. Anderson A general health policy model: Update and applications Health Serv Res 23 1988 203 235
20. R. Klein B.E.K. Klein S.E. Moss The Wisconsin epidemiologic study of diabetic retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more Arch Ophthalmol 107 1989 244 249
21. R. Klein B.E.K. Klein S.E. Moss Prevalence of microalbuminuria in older-onset diabetes Diabetes Care 16 1993 1325 1330
22. A. Laupacis D. Feeny A.S. Detsky How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 1992 473 481
23. R.G. Nelson W.C. Knowler D.J. Pettitt Incidence and determinants of elevated urinary albumin excretion in Pima Indians with NIDDM Diabetes Care 18 1995 182 187
24. T.R. Pedersen J. Kjekshus K. Berg for the Scandinavian Simvastatin Survival Study Group Cholesterol lowering and the use of healthcare resources Circulation 93 1996 1796 1802
25. Renal data system USRDS 1995 Annual Data Report 1995 National Institutes of Health, NIDDK Bethesda, MD
26. Renal data system USRDS 1993 Annual Data Report 1993 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD 14
27. R.J. Rubin W.M. Altman D.N. Mendelson Health care expenditures for people with diabetes mellitus, 1992 J Clin Endocrinol Metab 78 1994 809A 809F
28. L.B. Russell The role of prevention in health reform N Engl J Med 329 1993 352 354
29. A.R. Somers Why not try preventing illness as a way of controlling Medicare costs? N Engl J Med 311 1984 853 856
30. T.O. Tengs M.E. Adams J.S. Pliskin Five-hundred life-saving interventions and their cost-effectiveness Risk Anal 15 1995 369 390
31. The Diabetes Control and Complications Trial Research Group Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial JAMA 276 1996 1409 1415
32. The Diabetes Control and Complications Trial Research Group Resource utilization and costs of care in the Diabetes Control and Complications Trial Diabetes Care 18 1995 1468 1478
33. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 1993 977 986
34. The Diabetes Control and Complications Trial Research Group The influence of intensive diabetes therapy on quality of life outcomes in the Diabetes Control and Complications Trial Diabetes Care 19 1996 195 203
35. G.W. Torrance W. Furlong D. Feeny Multi-attribute preference functions: Health utilities index Pharmaco Economics 9 1995 503 520
36. I.S. Udvarhelyi G.A. Colditz A. Rai Cost-effectiveness and cost-benefit analyses in the medical literature: Are the methods being used correctly? Ann Intern Med 116 1992 238 244
37. M.C. Weinstein The costs of prevention J Gen Intern Med 5 suppl 1990 S89 S92